A B S T R A c T Apolipoprotein E (apoprotein E or apo-E) from type III hyperlipoproteinemic subjects with the E2/2 homnozygous phenotype displays both structural and receptor binding heterogeneity. The apo-E from all subjects thus far studied, however, has been functionally defective, though to different degrees. Although nearly every type 111 hyperlipoproteinemic subject has the E2/2 phenotype, 95-99% of the people with this same phenotype do not display type 111 hyperlipoproteinemia, nor do they have elevated plasma cholesterol levels. Consequently, it became important to determine whether the apo-E2 from hypo-and normocholesterolemic individuals with the E2/2 phenotype is also functionally abnormal. To do this, apo-E2 was isolated from two hypo-, two normo-, and two hy percholesterolemic homozygous E2/2 subjects. The apo-E2 was recombined with phospholipid vesicles and tested for its ability to displace l251 -Iio density lipoproteins (LDL) from apo-B,E (LDL) receptors on human fibroblasts. The apo-E2 from all six subjects was found to be severely defective in receptor binding (<2% of the binding activity of normal apo-E-3). In all cases, the binding activity of the apo-E2 was increased 10-to 20-fold by treating the apoproteins with cysteamine, a reagent that converts cysteine residues to positively charged lysine analogues. The cxsteine content of each apo-E wsas determined by monitoring the .Xddress corresp)ondenec to Dr. Mlahlev. R ccciLed for publicat ion 22 Oct obe r 1982. change in the isoelectric focusing position of the cysteamine-treated apo-E2. Using this method, it was found that the apo-E2 from each subject contained two cysteine residues per mole. A partial sequence analysis of the cysteine-containing regions of the apo-E from three of the six subjects indicated that the two cysteine residues were at residues 112 and 158 in the amino acid sequence. The cysteine at residue 158 has previously been implicated in the severe binding defect of the apo-E2 from a type III hyperlipoproteinemic subject. Since the apo-E2 of the hvpo-, normo-, and hypercholesterolemic subjects in this study all displayed a severe functional abnormality, it is apparent that factors in addition to the defective receptor binding activity of the apo-E2 are necessary for the manifestation of type III hyperlipoproteinenmia.
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I N TRODUCT ION
The complex isoform pattern displayed by human apolipoprotein E (apoprotein E or apo-E)' is due to primary structural differences and posttranslational modification. Utermann and his colleagues (1) (2) (3) were the first to demonstrate the genetic polymorphism of the apo-E isoforms. Since then, evidence has been presented to show that this genetic polymorphism results from the presence of multiple alleles at a single genetic Abbreviationl.s used in this paper: apo, apolipoprotein; I)\1I(, (liluvN\risto\ llhosl)haitidvicholine. locus and the posttranslational sialylation of apo-E (4, 5) . Recently, we found that the genetically determined, major (unsialylated) isoforms of apo-E (E2, E3, and E4) differ from one another in primary structure (6, 7) . This indicates that the genetic control is at the level of the structural gene for apo-E and confirms the prediction of the Zannis-Breslow hypothesis (4, 5) .
Utermann et al. (8) demonstrated that a specific apo-E phenotype is associated with the lipid disorder type III hyperlipoproteinemia (primary dysbetalipoproteinemia), an observation confirmed by others (9, 10) . Individuals with this disorder are homozygous for E2 (8) and have a hyperlipoproteinemia characterized by the accumulation of apo-E-enriched chylomicron and very low density lipoproteins (VLDL) remnants (of both hepatic and intestinal origin) in the plasma (11) . Because apo-E appears to be responsible for the receptor-mediated uptake of remnant lipoproteins by the liver (12) (13) (14) (15) (16) , and the mutant form of apo-E (E2) interacts poorly with lipoprotein receptors (17, 18) , it is likely that this mutant apo-E2 is responsible for the defective lipoprotein clearance in type III hyperlipoproteinemic subjects and the resulting dyslipoproteinemia in certain patients (13, (17) (18) (19) .
Population studies (1, 2, 5) have revealed a much higher frequency of the E2/2 homozygous phenotype (-1%) than would be expected from a specific association with type III hyperlipoproteinemia, which occurs in -0.01-0.04% of the population (20) . It within the E2/2 phenotype (24), it seemed important to understand the structural and receptor binding characteristics of the apo-E of hypo-and normocholesterolemic individuals with the E2/2 phenotype. In the present study, we will report evidence to show that apo-E2 from four hypo-and normocholesterolemic subjects appears to be structurally and functionally identical to the apo-E2 from severely hypercholesterolemic type III patients.
METHODS
Lipoprotein and apoprotein isolation and characterization. Lipoprotein density fractions were prepared from plasma by sequential ultracentrifugation (25) . Protein was determined by the method of Lowry et al. (26) . Total cholesterol and triglyceride levels were determined by using enzymatic procedures (Biodynamics/bmc, Boehringer Mannheim Corp., Indianapolis, IN). Phospholipid content of lipoproteins or apo-E* phospholipid complexes was determined from the phosphorus content (27) . The presence of f3-VLDL was ascertained by its electrophoretic migration on paper electrophoretograms (28) .
The d < 1.006 lipoproteins used for the preparation of apo-E were isolated from the plasma of subjects by ultracentrifugation for 16 (24) .
Peptides from the G-50 chromatography were subjected to sequence analysis, without further purification, in the presence of 2 mg of polybrene (Sigma Chemical Co.) on a Beckman 890C Sequencer using a 0.1 M Quadrol program (no. 122974) and standard Beckman reagents. Methods of analysis and criteria for identification of the phenylthiohydantoin amino acids by high performance liquid chromatography were as described (6, 24 1251-LDL. The methodology used for the maintenance of the cells and the conditions of the assay have been described (18, 29) .
RESULTS
Classification of subjects. Subjects were identified as part of a study on apo-E phenotypes in the German population (30) , and six subjects were selected for more detailed analysis on the basis of their apo-E phenotypes and plasma cholesterol levels. All six subjects had the E2/2 homozygous phenotype as determined by onedimensional isoelectric focusing (Fig. 1) . (Other selected data on these individuals are summarized in Table I .) Of the six subjects, two were classified as hypocholesterolemic, based on plasma cholesterol values below the 5th percentile as defined by the Lipid Research Clinics Prevalence Study (31) . Two subjects were normocholesterolemic, and two were hypercholesterolemic. The latter two had plasma cholesterol values that exceeded the 95th percentile (31) . Of the hypercholesterolemic subjects, one (H.-O.K.) was clearly a type III hyperlipoproteinemic by all of the usual criteria. He had xanthomatosis and both coronary and peripheral vascular disease. The other subject (W.H.) had symptoms of type III hyperlipoproteinemia in some respects, i.e., a borderline VLDL-cholesterol/plasma triglyceride ratio and greatly elevated VLDL-cholesterol and VLDL-triglyceride levels. His relatively young age might have been a factor in his failure to display all of the clinical criteria of the dis- order. All of the subjects showed some evidence of dyslipoproteinemia (i.e., ,B-VLDL in the plasma), which has previously been demonstrated by other investigators to be prevalent within the E2/2 phenotype (22, 23) . The subjects also had reduced LDL levels (as judged by LDL-cholesterol values); this is also consistent with previous findings for this phenotype (22) . Characterization of the apo-E2 from the six subjects. The mutant forms of apo-E2 that have thus far been described differ from apo-E3 by a single amino acid substitution of a cysteine residue for an arginine within the amino acid sequence (7, 24) . Apo-E3 contains a single residue of cysteine, whereas the apo-E2 mutants have two residues of cysteine per mole of protein. The number of cysteine residues per mole of apo-E can be rapidly determined by reacting the apo-E with the reagent cysteamine (6, 18, 24) . For each cysteine residue present, cysteamine treatment adds a single positive charge to the apo-E, and by isoelectric focusing, the cysteamine-treated apo-E assumes a pl differing from the untreated apo-E by one unit of positive charge per cysteine. Thus, the mobility of cysteamine-treated apo-E3 is altered by one positive charge unit, and the mobility of cysteamine-treated apo-E2, which contains two cysteine residues, is altered by two positive charge units. As shown in Fig.  1 , for two of the subjects, the mobility of the apo-E2 was altered by two units of charge after cysteamine treatment. The same result was observed for the apo-E2 of the other four subjects (data not shown). The cysteine content of the apo-E2 from three of the subjects was determined by direct sequence analysis, and these results confirmed that two residues of cysteine were present (see results described below).
Receptor binding of the apo-E2. The apo-E from Type (31) .
ND, no data.
each subject was recombined with DMPC and tested for its ability to bind to the apo-B,E receptors of human fibroblasts. In addition, apo-E from each subject was treated with cysteamine, and its binding activity was compared with that of untreated apo-E. A representative competition experiment is shown in Fig. 2 , and a summary of all binding experiments is presented in Table II . In all cases, the receptor binding of apo-E2 was severely defective compared with that of normalbinding apo-E3, which served as the control. Treatment of the apo-E of the subjects with cysteamine invariably resulted in a large increase in binding activity. Markedly defective binding (<2% of the binding activity of normal apo-E3) and a large increase in binding after cysteamine treatment (10-to 20-fold) have previously been demonstrated (18, 24) for the apo-E2 of a classical type III hyperlipoproteinemic subject (D.R.), whose apo-E2 amino acid sequence has been reported (7, 24) .
The similarity in binding activity of the apo-E from the six subjects in this study and from subject D.R. of a previous study suggested a structural similarity in the apo-E of these subjects regardless of whether they were hypo-, normo-, or hypercholesterolemic. Recently, it has been established that there is a structural heterogeneity in the apo-E2 from type III hyperlipoproteinemic individuals of the E2/2 homozygous phenotype (24) . This structural heterogeneity is due to differences in the location of one of the two cysteine residues that occur in apo-E2. The structural heterogeneity has been directly correlated with the functional heterogeneity, i.e., the severity of the binding defect, which has previously been documented in certain type III hyperlipoproteinemic subjects (17, 18) . Therefore, it seemed necessary to determine, where possible, the location of the cysteine residues in the apo-E of the German subjects.
A partial sequence analysis of the cysteine-containing region of the apo-E2 was undertaken as previously described (6, 24) . Limitations in the availability of sufficient apo-E for this type of analysis meant that apo-E from only three of the six subjects (W.G., W.H., and H.-O.K.) could be studied. Column-purified apo-E was digested with CNBr and the peptides were separated by gel chromatography. Cysteine-containing peptides (Fig. 3) were subjected to amino acid and sequence analyses (Tables III and IV) . Both the composition and sequence of the small peptide, CB4 (Fig. 3) , were identical for the apo-E from subjects W.G., W.H., and H.-O.K. Furthermore, the peptide was identical to the comparable peptide of the apo-E2 from other type III subjects and of the apo-E3 from subjects without type III hyperlipoproteinemia (6, 7, 24) . This peptide, corresponding to residues 109-125 in the apo-E sequence (7), had the following structure: Glu-Asp-Val-Cys-GlyArg-Leu-Val-Gln-Tyr-Arg-Gly-Glu-Val-Gln-Ala-Met.
It has previously been shown that the cysteine residue of this peptide (position 112 in the sequence) is not involved in the interaction of apo-E3 with receptors (18) and, as could be expected, there was no effect on binding when this cysteine residue was replaced by arginine, as occurs in apo-E4 (6, 18, 24 
DISCUSSION
The structural and receptor binding studies on the apo-E2 from hypo-, normo-, and hypercholesterolemic E2/ 2 subjects indicated that the apo-E from these individuals was ide ntical. A partial amino acid sequence analysis of the apo-E2 from three of these E2 homozygous subjects revealed that the cysteine-containing segment of the polypeptide chain (corresponding to residues 109-177) was also identical to that of the apo-E from the type III hyperlipoproteinemic subject D.R. (7) . This is the region of the apo-E molecule in which all of the known amino acid substitutions occur (24) and is also the region of the molecule that has been implicated in receptor binding (32) . A cysteine for arginine substitution was evident in the apo-E2 of subjects H.-O.K., W.H., and W.G. in this critical region of the molecule (residue 158), as well as in that of subject D.R. (7) . Furthermore, the apo-E2 from all of these subjects was severely defective in receptor binding activity (<2% of the binding activity of normal apo-E3) and demonstrated a marked increase in binding after cysteamine treatment.
Recently, the structure of the apo-E2 from an additional type III hyperlipoproteinemic subject (W.M.) was shown to differ from normal apo-E3 by a cysteine/ arginine interchange at residue 145 (24) . This mutant form of apo-E2 was much less defective than the other mutant apo-E2 in respect to binding activity (demonstrating -50% of the activity of normal apo-E). This along with other evidence indicates that binding heterogeneity correlates with structural heterogeneity (24, 32) . Therefore, the similarity in binding activity Compiled from competitive binding experiments as described in the legend to Fig. 2 . A logit-logit plot of binding data was used to determine the 50% competition point. and the presence of two residues of cysteine (as determined by partial sequence analyses or cysteamine treatment) in the apo-E of all six E2/2 subjects in the present study suggest that these proteins were structurally identical. One must conclude that the presence of receptor-defective apo-E2, as observed in these ompositions are given in residues per mole; numbers in parentheses for CB4 are residues determined from sequence. I Determined as cysteic acid after performic acid oxidation. § Determined as homoserine lactone.
hypo-, normo-, and hypercholesterolemic E2/2 subjects, may not be sufficient for the expression of type III hyperlipoproteinemia.
The development of severe type III hyperlipoproteinemia (with hypercholesterolemia and hypertriglyceridemia) may require the existence of genetic or metabolic abnormalities in addition to the presence of a functionally defective form of apo-E. One is struck by the variety of environmental and hormonal factors that exacerbate or modulate the severity of the expression of the type III disorder, including age, sex, diet, obesity, hypothyroidism, and diabetes (21 It is reasonable to speculate that the chylomicron remnants of normolipidemic E2 homozygous subjects may be cleared by some other mechanism. It is possible that under these conditions the apo-B in chylomicron remnants of these subjects mediates the uptake of the remnants by the hepatic lipoprotein receptors. The efficiency of this process would depend on the level of the expression of the hepatic apo-B,E receptors. The expression of these receptors would be critical in determining the extent of the lipoprotein abnormality in subjects with defective apo-E. Furthermore, it should be recalled that, even though all six of these subjects had severely defective apo-E, the apo-E did display a low level of binding activity, which may account for some clearance of lipoproteins by either the apo-B,E or apo-E receptors.
These two distinct hepatic lipoprotein receptors, the apo-B,E (LDL) receptor and the apo-E receptor, are the primary lipoprotein receptors in the livers of man and certain animals. They are both capable of interacting with chylomicron remnants in vitro (15, 16) . The hepatic apo-E receptor is relatively refractory to changes in expression that are brought about by metabolic perturbations (15, 16) . However, the expression of hepatic apo-B,E receptors is rapidly and efficiently modulated by diet, drugs, hormones, and varying plasma concentrations of lipoproteins and bile acids (14) (15) (16) 33) . In addition, the expression of the hepatic apo-B,E receptor is age-dependent. Young immature animals reveal very high levels of hepatic apo-B,E receptors, whereas adult animals express very low levels of hepatic apo-B,E receptors. (The hepatic apo-E receptors are not affected by age). Adult human livers, like those of adult animals, reveal very low levels of apo-B,E receptors (16) . This is significant when considering that the manifestations of type III hyperlipoproteinemia are very age-dependent: they rarely, if ever, occur before adulthood (21) . It is reasonable to speculate that the hyperlipidemia may result at this time because of the inability of the lower level of hepatic apo-B,E receptors to clear the chylomicron remnants.
The sensitivity of this lipid disorder to diet, drugs, and hormonal balance further suggests a role for the expression, or lack of expression, of the hepatic apo- Type B,E receptors. For example, type III hyperlipoproteinemia in women most often occurs after menopause (21) , and in these individuals the disorder is particularly responsive to estrogen therapy (34) (35) (36) . The induction of hepatic apo-B,E receptors in animals given estrogen, though at nonpharmacologic doses, has previously been reported (37, 38) . The role of hypothyroidism in the exacerbation of type III hyperlipoproteinemia (21) and the effects of thyroid hormone on receptor-mediated lipoprotein catabolism (39) further suggest that a modulation of hepatic apo-B,E receptors may be involved in the type III disorder. Those subjects homozygous for the E2/2 phenotype who do not have hyperlipoproteinemia may be capable of maintaining high levels of hepatic apo-B,E receptor activity and are therefore able to clear certain lipoproteins from the plasma (e.g., chylomicron remnants, which contain the defective apo-E).
The development of type III hyperlipoproteinemia may also result, at least in part, from an overproduction of hepatic cholesterol and/or hepatic VLDL. A primary cause for the overproduction of hepatic VLDL could be the impaired clearance of chylomicron remnants, which results in a deficiency in the delivery of cholesterol to the liver. As a result, hepatic cholesterol biosynthesis, and possibly hepatic VLDL production, could be stimulated. These newly secreted hepatic VLDL, either because of the presence of defective apo-E or because of an abnormal particle composition, may not be metabolized normally and thus could accumulate in the plasma. Furthermore, there may be several secondary causes for hepatic overproduction of VLDL and cholesterol. Various (41) .
It is clear that the expression of type III hyperlipoproteinemia is complex. The description of the abnormalities in the apo-E2 of these subjects provides a basis for understanding this lipoprotein disorder; however, other factors clearly interact to modulate its expression. The considerations discussed represent testable hypotheses.
